Caroline Even

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

J. Guigay, Jérôme Fayette, Cédrik Lafond et al. · Journal of Clinical Oncology · 2019 · 82 citations

Medicine, Oncology, Pharmacology +14

Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study

Loren S. Michel, Antonio Jimeno, Ammar Sukari et al. · Clinical Cancer Research · 2024 · 20 citations

Medicine, Oncology, Cancer Pharmacology +16

Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).

Caroline Even, Kevin J. Harrington, Erminia Massarelli et al. · Journal of Clinical Oncology · 2024 · 15 citations

Life Sciences, Immunology, Pharmacology +13

Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)

Ezra E.W. Cohen, Jérôme Fayette, Amaury Daste et al. · Cancer Research · 2023 · 11 citations

Medicine, Oncology, Pharmacology +17

First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr–Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies

A. Dimitrios Colevas, Zahra Talebi, Elizabeth Winters et al. · Clinical Cancer Research · 2025 · 11 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Oncology +13